cord blood mesenchymal stem cells

Cord blood mesenchymal stem cells (CB-MSC) are multipotent stromal cells isolated from the mononuclear cell fraction of human umbilical cord blood. These cells have the capacity to differentiate into a variety of cell types including bone, cartilage, muscle, and fat. Unlike hematopoietic stem cells from cord blood—which are primarily used for reconstituting the hematopoietic and immune systems—CB-MSCs are being investigated for their regenerative properties and immunomodulatory effects. They do not require HLA matching or chemotherapy prior to administration due to their low immunogenicity[1]. CB-MSCs exert therapeutic effects mainly through paracrine signaling by secreting cytokines and growth factors that modulate inflammation, promote tissue repair, and support regeneration[5][6]. Clinical research is ongoing in a wide range of indications including autoimmune diseases (such as type 1 diabetes and Crohn’s disease), neurodegenerative disorders (such as Parkinson’s disease), cardiovascular diseases (such as myocardial infarction), orthopedic conditions (like osteoarthritis), COVID-19-related lung injury, autism spectrum disorder, cerebral palsy, graft-versus-host disease (GvHD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), liver diseases, spinal cord injuries, kidney disease/diabetic nephropathy[4][6][8][9][10]. The majority of clinical trials using perinatal MSCs derive them from umbilical cord tissue rather than directly from cord blood; only about 4% of recent trials use true CB-MSCs[7][9].

Other names

cord blood MSCCB-MSCumbilical cord blood-derived mesenchymal stem cells